These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 10847132)

  • 1. Serum levels of hepatitis C virus RNA predict non-response to interferon therapy: comparison of two commercial assays.
    Soffredini R; Rumi MG; Del Ninno E; Parravicini ML; Russo A; Colombo M
    J Viral Hepat; 1999 Jan; 6(1):65-71. PubMed ID: 10847132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative evaluation of the total hepatitis C virus core antigen, branched-DNA, and amplicor monitor assays in determining viremia for patients with chronic hepatitis C during interferon plus ribavirin combination therapy.
    Veillon P; Payan C; Picchio G; Maniez-Montreuil M; Guntz P; Lunel F
    J Clin Microbiol; 2003 Jul; 41(7):3212-20. PubMed ID: 12843066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evaluation of the automated COBAS AMPLICOR HCV MONITOR test version 2.0 for quantifying serum hepatitis C virus RNA and comparison to the quantiplex HCV version 2.0 test.
    Yu ML; Chuang WL; Dai CY; Chen SC; Lin ZY; Hsieh MY; Wang LY; Chang WY
    J Clin Microbiol; 2000 Aug; 38(8):2933-9. PubMed ID: 10921954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical application of the Quantiplex HCV RNA 2.0 and Amplicor HCV Monitor assays for quantifying serum hepatitis C virus RNA.
    Yu ML; Chuang WL; Chen SC; Lin ZY; Hsieh MY; Wang LY; Chang WY
    J Clin Pathol; 1999 Nov; 52(11):807-11. PubMed ID: 10690168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of viral loads in patients with chronic hepatitis C with AMPLICOR HCV MONITOR version 1.0, COBAS HCV MONITOR version 2.0, and QUANTIPLEX HCV RNA version 2.0 assays.
    Martinot-Peignoux M; Le Breton V; Fritsch S; Le Guludec G; Labouret N; Keller F; Marcellin P
    J Clin Microbiol; 2000 Jul; 38(7):2722-5. PubMed ID: 10878070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of relapse or sustained response in biochemical responders by serum hepatitis C virus RNA monitoring during interferon therapy.
    Colloredo G; Roffi L; Brunetto MR; Leandro G; Brugnetti B; Bissoli F; Scalori A; Mancia G; Civardi E; Idéo G; Bonino F; Bellati G
    J Viral Hepat; 1999 Sep; 6(5):373-80. PubMed ID: 10607253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy.
    Takahashi M; Saito H; Higashimoto M; Atsukawa K; Ishii H
    J Clin Microbiol; 2005 Jan; 43(1):186-91. PubMed ID: 15634970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of HCV RNA assays for the detection and quantification of hepatitis C virus RNA levels in serum of patients with chronic hepatitis C treated with interferon.
    Trabaud MA; Bailly F; Si-Ahmed SN; Chevallier P; Sepetjan M; Colucci G; Trépo C
    J Med Virol; 1997 May; 52(1):105-12. PubMed ID: 9131466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of reverse transcription-polymerase chain reaction and branched-chain DNA assays for hepatitis C virus RNA in patients receiving interferon treatment. Consensus Interferon Study Group.
    Pockros PJ; Bain VG; Hunter EB; Conrad A; Balart A; Hollinger FB; Albert D
    J Viral Hepat; 1999 Mar; 6(2):145-50. PubMed ID: 10607226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus (HCV) RNA level determined by second-generation branched-DNA probe assay as predictor of response to interferon treatment in patients with chronic HCV viremia.
    Furusyo N; Hayashi J; Kashiwagi K; Nakashima H; Nabeshima S; Sawayama Y; Kinukawa N; Kashiwagi S
    Dig Dis Sci; 2002 Mar; 47(3):535-42. PubMed ID: 11911338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of genotypes on the quantification of hepatitis C virus (HCV) RNA in clinical samples using the Amplicor HCV Monitor Test and the Quantiplex HCV RNA 2.0 assay (bDNA).
    Tong CY; Hollingsworth RC; Williams H; Irving WL; Gilmore IT
    J Med Virol; 1998 Jul; 55(3):191-6. PubMed ID: 9624605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the clinical usefulness of COBAS AMPLICOR HCV MONITOR assay (ver2.0): Comparison with AMPLICOR HCV MONITOR assay (ver1.0) and HCV core protein level.
    Kawai S; Yokosuka O; Imazeki F; Saisho H; Mizuno C
    J Med Virol; 2002 Nov; 68(3):343-51. PubMed ID: 12226820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of twice-daily administration of interferon-beta for chronic hepatitis C.
    Kakizaki S; Takagi H; Yamada T; Ichikawa T; Abe T; Sohara N; Kosone T; Kaneko M; Takezawa J; Takayama H; Nagamine T; Mori M
    J Viral Hepat; 1999 Jul; 6(4):315-9. PubMed ID: 10607246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of early virological response to antiviral therapy by comparing four assays for HCV RNA quantitation using the international unit standard: implications for clinical management of patients with chronic hepatitis C virus infection.
    Halfon P; Pénaranda G; Bourlière M; Khiri H; Masseyeff MF; Ouzan D
    J Med Virol; 2006 Feb; 78(2):208-15. PubMed ID: 16372298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of 3 quantitative HCV RNA assays--accuracy of baseline viral load to predict treatment outcome in chronic hepatitis C.
    Reichard O; Norkrans G; Frydén A; Braconier JH; Sönnerborg A; Weiland O
    Scand J Infect Dis; 1998; 30(5):441-6. PubMed ID: 10066040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of different hepatitis C serological assays in the treatment of chronic hepatitis C with interferon alpha.
    Kobayashi M; Chayama K; Arase Y; Tsubota A; Saitoh S; Suzuki Y; Kobayashi M; Kobayashi M; Ikeda K; Matsuda M; Koike H; Hashimoto M; Kumada H
    J Gastroenterol; 1999 Feb; 34(1):94-9. PubMed ID: 10204617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment, by transcription-mediated amplification, of virologic response in patients with chronic hepatitis C virus treated with peginterferon alpha-2a.
    Sarrazin C; Hendricks DA; Sedarati F; Zeuzem S
    J Clin Microbiol; 2001 Aug; 39(8):2850-5. PubMed ID: 11474002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic range of hepatitis C virus RNA quantification with the Cobas Ampliprep-Cobas Amplicor HCV Monitor v2.0 assay.
    Gourlain K; Soulier A; Pellegrin B; Bouvier-Alias M; Hézode C; Darthuy F; Rémiré J; Pawlotsky JM;
    J Clin Microbiol; 2005 Apr; 43(4):1669-73. PubMed ID: 15814982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and quantitative (COBAS AMPLICOR HCV monitor 2.0 versus VERSANT HCV RNA 3.0) assays for hepatitis C virus (HCV) RNA detection and quantification: impact on diagnosis and treatment of HCV infections.
    Desombere I; Van Vlierberghe H; Couvent S; Clinckspoor F; Leroux-Roels G
    J Clin Microbiol; 2005 Jun; 43(6):2590-7. PubMed ID: 15956369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative measurement of serum HCV RNA in patients with chronic hepatitis C: comparison between Amplicor HCV monitor system and branched DNA signal amplification assay.
    Lu RH; Hwang SJ; Chan CY; Chang FY; Lee SD
    J Clin Lab Anal; 1998; 12(2):121-5. PubMed ID: 9524297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.